Cargando…

The value of maintaining normokalaemia and enabling RAASi therapy in chronic kidney disease

BACKGROUND: People with chronic kidney disease (CKD) are at an increased risk of developing hyperkalaemia due to their declining kidney function. In addition, these patients are often required to reduce or discontinue guideline-recommended renin-angiotensin-aldosterone system inhibitor (RAASi) thera...

Descripción completa

Detalles Bibliográficos
Autores principales:	Evans, Marc, Palaka, Eirini, Furuland, Hans, Bennett, Hayley, Linde, Cecilia, Qin, Lei, McEwan, Phil, Bakhai, Ameet
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357372/ https://www.ncbi.nlm.nih.gov/pubmed/30704421 http://dx.doi.org/10.1186/s12882-019-1228-y

Ejemplares similares

Serum potassium as a predictor of adverse clinical outcomes in patients with chronic kidney disease: new risk equations using the UK clinical practice research datalink
por: Furuland, Hans, et al.
Publicado: (2018)

Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21 334 patients in the UK
por: Linde, Cecilia, et al.
Publicado: (2019)

Real‐World Associations of Renin–Angiotensin–Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New‐Onset Chronic Kidney Disease or Heart Failure in the United Kingdom
por: Linde, Cecilia, et al.
Publicado: (2019)

The Impact of CKD Anaemia on Patients: Incidence, Risk Factors, and Clinical Outcomes—A Systematic Literature Review
por: Palaka, Eirini, et al.
Publicado: (2020)

Patiromer and maintenance of RAASi therapy in hyperkalemic medicare patients
por: Desai, Nihar R., et al.
Publicado: (2019)

Management of RAASi-associated hyperkalemia in patients with cardiovascular disease
por: Silva-Cardoso, José, et al.
Publicado: (2021)

Association between hyperkalemia, RAASi non-adherence and outcomes in chronic kidney disease
por: Santoro, Antonio, et al.
Publicado: (2021)

Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia
por: Kanda, Eiichiro, et al.
Publicado: (2023)

Cost effectiveness of sodium zirconium cyclosilicate for the treatment of hyperkalaemia in patients with CKD in Norway and Sweden
por: Kim, Kun, et al.
Publicado: (2022)

The Health Economic Value of Changes in Glycaemic Control, Weight and Rates of Hypoglycaemia in Type 1 Diabetes Mellitus
por: McEwan, Phil, et al.
Publicado: (2016)

Assessing the economic value of maintained improvements in Type 1 diabetes management, in terms of HbA(1c), weight and hypoglycaemic event incidence
por: McEwan, P., et al.
Publicado: (2018)

Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model
por: Bennett, Hayley, et al.
Publicado: (2019)

Assessment of Unmet Clinical Need in Type 2 Diabetic Patients on Conventional Therapy in the UK
por: Bennett, Hayley, et al.
Publicado: (2014)

Assessing the Long-Term Impact of Treating Hepatitis C Virus (HCV)-Infected People Who Inject Drugs in the UK and the Relationship between Treatment Uptake and Efficacy on Future Infections
por: Bennett, Hayley, et al.
Publicado: (2015)

Optimization of RAASi Therapy with New Potassium Binders for Patients with Heart Failure and Hyperkalemia: Rapid Review and Meta-Analysis
por: Montagnani, Andrea, et al.
Publicado: (2021)

Evaluation of Insulin Use and Value for Money in Type 2 Diabetes in the United Kingdom
por: Gordon, Jason, et al.
Publicado: (2013)

Predicting atrial fibrillation in primary care using machine learning
por: Hill, Nathan R., et al.
Publicado: (2019)

Prescription of renin‐angiotensin‐aldosterone system inhibitors (RAASi) and its determinants in patients with advanced CKD under nephrologist care
por: Pecoits‐Filho, Roberto, et al.
Publicado: (2019)

RAASi Therapy Attenuates the Association between 24-h Urinary Potassium Excretion and Dietary Potassium Intake in CKD Patients
por: Giannese, Domenico, et al.
Publicado: (2023)

A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure
por: Ward, Thomas, et al.
Publicado: (2023)

Estimating the Clinical and Economic Benefit Associated with Incremental Improvements in Sustained Virologic Response in Chronic Hepatitis C
por: McEwan, Phil, et al.
Publicado: (2015)

Validation of the UKPDS 82 risk equations within the Cardiff Diabetes Model
por: McEwan, Philip, et al.
Publicado: (2015)

"Bronchial Artery Delivery of Viral Vectors for Gene delivery in Cystic Fibrosis; Superior to Airway Delivery?"
por: Bakhai, Ameet, et al.
Publicado: (2002)

A Retrospective, Case-Note Survey of Type 2 Diabetes Patients Prescribed Incretin-Based Therapies in Clinical Practice
por: Evans, Marc, et al.
Publicado: (2012)

Real‐world data on the incidence, mortality, and cost of ischaemic stroke and major bleeding events among non‐valvular atrial fibrillation patients in England
por: Bakhai, Ameet, et al.
Publicado: (2020)

Characterizing the relationship between health utility and renal function after kidney transplantation in UK and US: a cross-sectional study
por: Neri, Luca, et al.
Publicado: (2012)

Understanding Patient Perspectives of the Impact of Anemia in Chronic Kidney Disease: A United States Patient Survey
por: Grandy, Susan, et al.
Publicado: (2022)

Understanding Patient Perspectives and Awareness of the Impact and Treatment of Anemia with Chronic Kidney Disease: A Patient Survey in China
por: Hao, Chuan-Ming, et al.
Publicado: (2021)

A model to predict disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD): the ADPKD Outcomes Model
por: McEwan, Phil, et al.
Publicado: (2018)

Treatment choice, medication adherence and glycemic efficacy in people with type 2 diabetes: a UK clinical practice database study
por: Gordon, Jason, et al.
Publicado: (2018)

Managing glycaemia in older people with type 2 diabetes: A retrospective, primary care‐based cohort study, with economic assessment of patient outcomes
por: Gordon, Jason, et al.
Publicado: (2017)

Estimating the Economic and Clinical Value of Reducing Antimicrobial Resistance to Three Gram-negative Pathogens in Japan
por: Matsumoto, Tetsuya, et al.
Publicado: (2021)

Drug treatment patterns and work productivity in chronic kidney disease patients with anemia in China: cross sectional analysis of real-world data
por: van Haalen, Heleen, et al.
Publicado: (2020)

Comment on Montagnani et al. Optimization of RAASi Therapy with New Potassium Binders for Patients with Heart Failure and Hyperkalemia: Rapid Review and Meta-Analysis. J. Clin. Med. 2021, 10, 5483
por: Zarzuela, Donna, et al.
Publicado: (2022)

Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes
por: Evans, Marc, et al.
Publicado: (2019)

Protecting blinded trials in electronic hospital systems
por: Sydes, Matthew R, et al.
Publicado: (2022)

Implementation of a decision aid for recognition and correction of volume alterations (Recova(®)) in haemodialysis patients
por: Stenberg, Jenny, et al.
Publicado: (2020)

Costs and Healthcare Resource Use Associated with Risk of Cardiovascular Morbidity in Patients with Chronic Kidney Disease: Evidence from a Systematic Literature Review
por: Darlington, Oliver, et al.
Publicado: (2021)

The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-on Therapy to Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus
por: Gordon, Jason, et al.
Publicado: (2016)

Economic Modelling of Chronic Kidney Disease: A Systematic Literature Review to Inform Conceptual Model Design
por: Sugrue, Daniel M., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_a4g34hss2pn1d5ke6isnnj7kip